An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.

Lenalidomide is an effective new agent for the treatment of patients with myelodysplastic syndrome (MDS), an acquired hematopoietic disorder characterized by ineffective blood cell production and a predisposition to the development of leukemia. Patients with an interstitial deletion of Chromosome 5q...

Full description

Bibliographic Details
Main Authors: Benjamin L Ebert, Naomi Galili, Pablo Tamayo, Jocelyn Bosco, Raymond Mak, Jennifer Pretz, Shyam Tanguturi, Christine Ladd-Acosta, Richard Stone, Todd R Golub, Azra Raza
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2008-02-01
Series:PLoS Medicine
Online Access:http://europepmc.org/articles/PMC2235894?pdf=render

Internet

http://europepmc.org/articles/PMC2235894?pdf=render

Similar Items